RECORDATI |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 50.4 EUR | -1.56% |
|
-0.20% | +3.22% |
| 05-10 | Futures bullish; Mib restarts at 34,300 level | AN |
| 05-09 | Mib up, Nexi and Prysmian good after accounts | AN |
| Sales 2024 * | 2.3B 2.5B 197B | Sales 2025 * | 2.44B 2.65B 209B | Capitalization | 10.54B 11.46B 903B |
|---|---|---|---|---|---|
| Net income 2024 * | 478M 520M 40.95B | Net income 2025 * | 524M 570M 44.89B | EV / Sales 2024 * | 5.15 x |
| Net Debt 2024 * | 1.3B 1.41B 111B | Net Debt 2025 * | 1.08B 1.18B 92.76B | EV / Sales 2025 * | 4.76 x |
| P/E ratio 2024 * |
22.9
x | P/E ratio 2025 * |
20.5
x | Employees | 4,455 |
| Yield 2024 * |
2.75% | Yield 2025 * |
3.03% | Free-Float | 46.44% |
More Fundamentals
* Assessed data
More news
Latest transcript on Recordati
More press releases
More news
| 1 day | -1.17% | ||
| 1 week | +0.20% | ||
| Current month | +1.10% | ||
| 1 month | -0.98% | ||
| 3 months | -2.92% | ||
| 6 months | +13.40% | ||
| Current year | +3.62% |
1 week
50.20
52.35
1 month
48.3853.40
Current year
47.2953.40
1 year
40.6253.40
3 years
34.5257.90
5 years
28.2657.90
10 years
11.3057.90
| Managers | Title | Age | Since |
|---|---|---|---|
Robert Koremans
CEO | Chief Executive Officer | 61 | 30/11/21 |
Luigi la Corte
DFI | Director of Finance/CFO | 54 | 31/10/19 |
Andrea Recordati
CHM | Chairman | 52 | 28/04/98 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Cathrin Petty
BRD | Director/Board Member | 51 | 11/06/18 |
Robert Koremans
CEO | Chief Executive Officer | 61 | 30/11/21 |
Andrea Recordati
CHM | Chairman | 52 | 28/04/98 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.52% | 5 M€ | +12.55% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 20/05/24 | 50.4 | -1.56% | 18 267 |
| 17/05/24 | 51.2 | +0.79% | 247,656 |
| 16/05/24 | 50.8 | -1.93% | 300,219 |
| 15/05/24 | 51.8 | +2.07% | 420,509 |
| 14/05/24 | 50.75 | +0.50% | 308,363 |
Real-time Borsa Italiana, May 20, 2024 at 09:04 am
More quotes
Recordati S.p.A. specializes in the research, development, production and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- pharmaceutical and OTC products (67.9%): for the treatment of viral infections, cardiovascular, dermatological, gynecological diseases, etc.;
- medicines for rare diseases (32.1%).
Net sales are distributed geographically as follows: Italy (15%), Europe (58.5%), America (17.5%), Australasia (6.2%) and Africa (2.8%).
Sector
Pharmaceuticals
Calendar
19/05/2024
- Final dividend
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
51.2
EUR
Average target price
52.24
EUR
Spread / Average Target
+2.03%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +3.62% | 11.46B | |
| +32.09% | 693B | |
| +29.39% | 584B | |
| -1.34% | 372B | |
| +20.34% | 332B | |
| +7.39% | 294B | |
| +13.81% | 239B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +8.49% | 168B |
- Stock Market
- Equities
- REC Stock
